International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer

  • On 19 October 2026 the FDA granted accelerated approval to Jemperli (dostarlimab) for stage II/III locally advanced rectal cancer.
  • The dostarlimab approval covers tumours that are microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
  • In the AZUR-1 trial of 154 patients, 71% were treated with dostarlimab alone, with no surgery or other therapy and no progression.
  • The 12-month sustained clinical complete response with dostarlimab was 47% by independent review.
Microscope image of human colon cancer cells
Microscope image of human colon cancer cells Photo: NIH Image Gallery via Wikimedia Commons (public domain)
Published:

The US Food and Drug Administration granted accelerated approval on 19 October 2026 to GSK's Jemperli (dostarlimab) for adults with stage II/III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test.

The trial

Approval rests on AZUR-1, a single-arm trial of 154 previously untreated patients who received dostarlimab 500 mg intravenously every 3 weeks for nine cycles. Patients with a clinical complete response entered non-operative management with close, regular monitoring.

Also read: FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer

Results

Of the 154 patients, 110 (71%) were treated with dostarlimab alone, received no other treatment and had no disease progression; 26 (17%) had surgery. The 12-month sustained clinical complete response rate was 47% by independent central review among 116 evaluable patients and 68% by investigators, and the objective response rate was 79%. With a median follow-up of 26.3 months, no patient with a complete or near-complete response had progressed.

Limits

This is an accelerated approval, so continued approval depends on confirmatory trials, and AZUR-1 had no comparison group. The label includes warnings for immune-mediated and infusion-related reactions.

Sources: US Food and Drug Administration (FDA), CancerNetwork, Healio

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is new in the FDA approval of dostarlimab?

On 19 October 2026 the FDA granted accelerated approval to dostarlimab (Jemperli) for stage II/III locally advanced rectal cancer that is MSI-H or dMMR.

How is dostarlimab given for rectal cancer?

Dostarlimab is given as 500 mg intravenously every 3 weeks for nine cycles, unless there is unacceptable toxicity or disease progression.

How many patients avoided surgery with dostarlimab?

In AZUR-1, 110 of 154 patients (71%) were treated with dostarlimab alone, with no surgery or other treatment and no disease progression.

What was the sustained complete response rate with dostarlimab?

The 12-month sustained clinical complete response with dostarlimab was 47% by independent review and 68% by investigators in AZUR-1.

Why is the dostarlimab rectal cancer approval accelerated?

The dostarlimab approval is based on a single-arm trial, so continued approval depends on confirming clinical benefit in later studies.

How would you rate this story?
3,516
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.